Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Abstract

This article demonstrates that the ATU system allows patients to benefit from therapeutic innovations before MA in Europe and USA, with full coverage by the healthcare system.